Teacher Retirement System of Texas Lowers Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Teacher Retirement System of Texas decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 3.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 13,988 shares of the biopharmaceutical company’s stock after selling 430 shares during the period. Teacher Retirement System of Texas’ holdings in Xenon Pharmaceuticals were worth $644,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of Xenon Pharmaceuticals by 417.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,546 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 6,895 shares in the last quarter. Moody Aldrich Partners LLC purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter worth $312,000. Barclays PLC raised its position in Xenon Pharmaceuticals by 3.7% during the third quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 342 shares during the period. Advisors Asset Management Inc. grew its position in shares of Xenon Pharmaceuticals by 25.9% in the third quarter. Advisors Asset Management Inc. now owns 10,188 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 2,096 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Xenon Pharmaceuticals by 2.2% during the third quarter. Arizona State Retirement System now owns 14,478 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 313 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, EVP Sherrington Robin sold 7,137 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the transaction, the executive vice president now directly owns 8,398 shares in the company, valued at approximately $388,659.44. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Steven Gannon sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $601,640.00. Following the completion of the transaction, the director now owns 2,000 shares of the company’s stock, valued at $92,560. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sherrington Robin sold 7,137 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the sale, the executive vice president now directly owns 8,398 shares in the company, valued at $388,659.44. The disclosure for this sale can be found here. Company insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Stock Down 0.2 %

XENE stock opened at $38.37 on Friday. Xenon Pharmaceuticals Inc. has a one year low of $27.99 and a one year high of $50.99. The firm’s 50 day moving average price is $41.65 and its 200-day moving average price is $42.10.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.07. The business had revenue of $1.00 million during the quarter. The firm’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.63) earnings per share. As a group, research analysts expect that Xenon Pharmaceuticals Inc. will post -2.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on XENE. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 10th. Wedbush decreased their price objective on Xenon Pharmaceuticals from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, May 10th. Citigroup decreased their price target on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Finally, Royal Bank of Canada cut their price objective on shares of Xenon Pharmaceuticals from $56.00 to $55.00 and set an “outperform” rating for the company in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.11.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.